IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0925719
(2013-06-24)
|
| 등록번호 |
US-8658667
(2014-02-25)
|
|
발명자
/ 주소 |
- Mudumba, Sreenivasu
- Nivaggioli, Thierry
- Takhar, Sudeep Kaur
|
| 출원인 / 주소 |
- Santen Pharmaceutical Co., Ltd.
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
0 인용 특허 :
132 |
초록
▼
Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stab
Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.
대표청구항
▼
1. A sealed vessel comprising a liquid formulation comprising rapamycin, polyethylene glycol and dissolved gases, wherein the liquid formulation does not comprise an antioxidant, has a percent of oxygen in the dissolved gases of no greater than 20%, and is in contact with a head space gas having no
1. A sealed vessel comprising a liquid formulation comprising rapamycin, polyethylene glycol and dissolved gases, wherein the liquid formulation does not comprise an antioxidant, has a percent of oxygen in the dissolved gases of no greater than 20%, and is in contact with a head space gas having no greater than 20% oxygen. 2. The sealed vessel of claim 1, wherein the ratio of head space gas volume to liquid formulation volume is no greater than 1.5, and the head space gas has no greater than 1 μl of oxygen per milligram of rapamycin in the liquid formulation. 3. The sealed vessel of claim 1, wherein the liquid formulation has a percent of oxygen in the dissolved gases of no greater than 17.5%. 4. The sealed vessel of claim 1, wherein the liquid formulation has a percent of oxygen in the dissolved gases of no greater than 16.5%. 5. The sealed vessel of claim 1, wherein the head space gas has no greater than 10% oxygen gas. 6. The sealed vessel of claim 1, wherein the head space gas has no greater than 5% oxygen gas. 7. The sealed vessel of claim 1, wherein the sealed vessel is a prefilled syringe. 8. The sealed vessel of claim 1, wherein the rapamycin in the liquid formulation is between 0.5% to 5% of the total weight of the liquid formulation. 9. The sealed vessel of claim 1, which is surrounded by secondary packaging to reduce light to which the liquid formulation is exposed. 10. The sealed vessel of claim 1, wherein the polyethylene glycol is between 90 to 99% of the total weight of the liquid formulation. 11. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least 1 month at 25° C. and 60% relative humidity. 12. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least 2 months at 25° C. and 60% relative humidity. 13. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least 3 months at 25° C. and 60% relative humidity. 14. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least about 3 months at 5° C. 15. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least about 1 year at 5° C. 16. The sealed vessel of claim 1, wherein the formula strength of the rapamycin is at least 90% for a period of at least 2 years at 5° C. 17. The sealed vessel of claim 1, wherein the liquid formulation further comprises ethanol. 18. The sealed vessel of claim 17, wherein the rapamycin is present at 2% w/w, the polyethylene glycol is PEG 400 and the PEG 400 is present at 94% w/w, and the ethanol is present at 4% w/w. 19. The sealed vessel of claim 1, wherein the rapamycin in the liquid formulation is between 0.5% to 5% of the total weight of the liquid formulation;the polyethylene glycol is between 90 to 99% of the total weight of the liquid formulation;the liquid formulation further comprises ethanol; andthe formula strength of the rapamycin is at least 90% for a period of at least 1 month at 25° C. and 60% relative humidity. 20. A sealed vessel comprising a liquid formulation comprising rapamycin, polyethylene glycol and dissolved gases, wherein the liquid formulation: has a percent of oxygen in the dissolved gases of no greater than 20%;is in contact with a head space gas having no greater than 20% oxygen; anddoes not comprise an antioxidant selected from the group consisting of ascorbic acid, citric acid, sodium sulfite, disodium EDTA, dithiothreitol (DTT), fumaric acid, beta hydroxyanisole (BHA), propyl gallate, alpha and beta tocopherols, toluene solfonic acid, tartaric acid, thioglycerol, thiourea, sodium formaldehyde sulfoxylate, sodium thiosulfate, glutamic acid, butylated hydroxytoluene (BHT), ascorbyl palmitate, benzyl alcohol, benzalkonium chloride, and maleic acid. 21. The sealed vessel of claim 20, wherein the liquid formulation further comprises ethanol. 22. The sealed vessel of claim 21, wherein the rapamycin is present at 2% w/w, the polyethylene glycol is PEG 400 and the PEG 400 is present at 94% w/w, and the ethanol is present at 4% w/w. 23. The sealed vessel of claim 22, wherein the formula strength of the rapamycin in the liquid formulation is at least 90% for a period of at least 1 month at 25° C. and 60% relative humidity.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.